Myelodysplastic syndromes are hematological malignancies characterized by ineffective
hematopoiesis and a high risk of progression to acute myeloid leukemia. Hypomethylating …

Recent developments in high-risk Myelodysplastic Neoplasms (HR MDS) treatment are
confronted with challenges in study design due to evolving drug combinations with …

Myelodysplastic Syndromes (MDSs) affect the elderly and can progress to Acute Myeloid
Leukemia (AML). Epigenetic alterations including DNA methylation and chromatin …

Since the US Food and Drug Administration (FDA) approvals of parenteral decitabine and
azacitidine, DNA methyltransferase inhibitors, otherwise referred to as DNA hypomethylating …

Hypomethylating agents (HMA), such as 5-azacitidine or decitabine, are currently used to
treat patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) until …

Gene silencing resulting from aberrant DNA methylation can lead to tumorigenesis.
Therefore, drugs that inhibit or interfere with DNA methylation have been used to reactivate …

Targeting epigenetic aberrations in cancer is now referred as to epigenetic therapy and
targeting DNA hypermethylation specifically has been very successful in the treatment of …

The DNA hypomethylating agents (HMA) azacitidine (AZA) and decitabine (DAC) improve
survival and transfusion independence in myelodysplastic syndrome (MDS) and enable a …

Oral hypomethylating agents (HMAs) represent a substantial potential boon for patients with
myelodysplastic syndrome (MDS) who have previously required between 5 and 7 visits per …

Introduction: There is evidence of the association of DNA methylation alterations with cancer
development and progression. Areas covered: This review will briefly discuss the basis of …